Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.

Circulating tumor cells (CTCs) have been implicated in tumor progression and prognosis. Techniques detecting CTCs in the peripheral blood of patients with non-small cell lung carcinoma (NSCLC) may help to identify individuals likely to benefit from early systemic treatment. However, the detection of CTCs with a single marker is challenging, owing to low specificity and sensitivity and due to the heterogeneity and rareness of CTCs. Herein, the probability of cell-free RNA content in the peripheral blood as a potential biomarker for detecting CTCs in cancer patients was investigated. An immunomagnetic enrichment of real-time reverse-transcription PCR (RT-PCR) technology for analysis of CTCs in NSCLC patients was also developed. The mRNA levels of four candidate genes, cytokeratin 7 (), E74-like factor 3 (), epidermal growth factor receptor (), and erythropoietin-producing hepatocellular carcinoma receptor B4 () that were significantly elevated in tumor tissues and peripheral blood mononuclear cells (PBMCs) were determined. The expression of and in tumor tissues and in PBMCs was associated with lymph node metastasis (all < 0.05). The expression of in PBMCs was correlated with age and in PBMCs correlated with histopathological type, respectively (all < 0.05). The expression of all four genes in tumor tissues and PBMCs was significantly correlated with the clinical stage (all < 0.01). Survival analysis showed that the patients with enhanced expression of , , , and mRNA in PBMCs had poorer disease-free survival (DFS) and overall survival (OS) than those without (all < 0.0001). The present study showed that this alteration of cell-free RNA content in peripheral blood might have clinical ramifications in the diagnosis and treatment of NSCLC patients.